Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $33.4 million.

  • Inmune Bio's Liabilities and Shareholders Equity fell 3680.04% to $33.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.4 million, marking a year-over-year decrease of 2901.63%. This contributed to the annual value of $39.6 million for FY2024, which is 3059.42% down from last year.
  • Latest data reveals that Inmune Bio reported Liabilities and Shareholders Equity of $33.4 million as of Q3 2025, which was down 3680.04% from $37.7 million recorded in Q2 2025.
  • Inmune Bio's 5-year Liabilities and Shareholders Equity high stood at $107.7 million for Q3 2021, and its period low was $33.4 million during Q3 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $65.6 million, with a median of $62.7 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 16336.86% in 2021, then plummeted by 3680.04% in 2025.
  • Over the past 5 years, Inmune Bio's Liabilities and Shareholders Equity (Quarter) stood at $99.9 million in 2021, then dropped by 18.16% to $81.8 million in 2022, then plummeted by 30.31% to $57.0 million in 2023, then crashed by 30.59% to $39.6 million in 2024, then fell by 15.68% to $33.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $33.4 million for Q3 2025, versus $37.7 million for Q2 2025 and $37.8 million for Q1 2025.